PEPTIDREAM INC.

PeptiDream reported H1 2026 revenue of JPY 9.2 billion, an operating loss of JPY 2.5 billion and EPS of -15.51 JPY. Management confirmed the full-year revenue target of JPY 32 billion and expects a return to profitability in fiscal year 2026. The clinical pipeline grew from 13 to 19 programs, and PDRadiopharma increased PET product sales by 30%. The stock reacted moderately positively, last trading at $1,007 (+1.49%). » Más en de.investing.com

PeptiDream will publish results for the quarter ended 31 December 2025 on 16 February 2026. On average, 3 analysts expect a quarterly loss per share of -5.695 JPY versus -20.100 JPY a year earlier. Four analysts forecast revenue to rise 18.27% to around 6.00 billion JPY. For the past fiscal year, consensus expectations (8 analysts) are for a loss per share of -10.743 JPY and annual revenue averaging 18.63 billion JPY. » Más en finanzen.net

PeptiDream will publish results for the quarter ended December 31, 2025 on February 16, 2026. Three analysts on average expect an EPS loss of −5,695 JPY per share (previous year −20,100 JPY). Revenue is estimated by four analysts at an average of 6.00 billion JPY, an increase of 18.27% from 5.07 billion JPY in the year-ago quarter. For the fiscal year, eight analysts on average see a loss per share of −10,743 JPY and revenue of 18.63 billion JPY. » Más en finanzen.net